Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ARID1A Gene Mutation: early-phase trial registry
2 of 3 indexed ARID1A Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
ARID1A Gene Mutation: 3 US clinical trials tracked, 2 recruiting.
ARID1A Gene Mutation is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Panagiotis Konstantinopoulos, MD, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition arid1a-gene-mutation
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
ARID1A Gene Mutation lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ARID1A Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ARID1A Gene Mutation is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co.
NCT05490472
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Panagiotis Konstantinopoulos, MD, PhD
NCT06518564
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma
NCT05226507
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on ARID1A Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ARID1A Gene Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ARID1A Gene Mutation page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 ARID1A Gene Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Panagiotis Konstantinopoulos, MD, PhD sponsors the most ARID1A Gene Mutation trials on record, review their full trial history before evaluating a specific study. See Panagiotis Konstantinopoulos, MD, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ARID1A Gene Mutation condition card totals 3 registered trials; most-linked intervention NXP800; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.